secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tarsus Pharmaceuticals, Inc. (TARS)
CIK:        0001819790
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0001193125-21-244642
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tarsus Pharmaceuticals appoints Rosemary A. Crane to Board; creates Science and Technology Committee
--------------------------------------------------------------------------------

- Crane appointed to Board effective Aug 11, 2021; will chair Audit and new Science and Technology Committees.
- Jason Tester resigned from Board and Audit Committee on Aug 10, 2021; no disagreement with Company.
- Wendy Yarno appointed Chair of Compensation Committee; Andrew Goldberg moved to Science and Technology Committee.
- Crane receives initial option for 20,000 shares under non-employee director compensation policy.
- Crane brings 30+ years pharma experience, including former CEO of MELA Sciences and Epocrates, senior roles at J&J and Bristol Myers Squibb.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819790/000119312521244642/0001193125-21-244642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819790/000119312521244642/d166164d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-244642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer